Symptom variability in COPD: a narrative review

References

• Viejo-BañuelosJLPueyo-BastidaAFueyo-RodriguezACharacteristics of outpatients with COPD in daily practice: The E4 Spanish projectRespir Med2006100122137214316831541
   PubMed Web of Science ®Google Scholar
• SorianoJBCalleMMontemayorTAlvarez-SalaJLRuiz-ManzanoJMiravitllesMThe general public’s knowledge of chronic obstructive pulmonary disease and its determinants: current situation and recent changesArch Bronconeumol2012489308315 Spanish22748482
   PubMed Web of Science ®Google Scholar
• FletcherCPetoRThe natural history of chronic airflow obstructionBr Med J19771607716451648871704
   PubMed Web of Science ®Google Scholar
• VestboJEdwardsLDScanlonPDChanges in forced expiratory volume in 1 second over time in COPDNew Engl J Med2011365131184119221991892
   PubMed Web of Science ®Google Scholar
• KohansalRMartinez-CamblorPAgustíABuistASManninoDMSorianoJBThe natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohortAm J Respir Crit Care Med2009180131019342411
   PubMed Web of Science ®Google Scholar
• CasanovaCde TorresJPAguirre-JaímeAThe progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohortAm J Respir Crit Care Med201118491015102121836135
   PubMed Web of Science ®Google Scholar
• AgustiACalverleyPMCelliBEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
   PubMed Web of Science ®Google Scholar
• López-CamposJLTreatment strategies in chronic obstructive pulmonary disease: a proposal for standardizationArch Bronconeumol20104612617620 Spanish20624667
   PubMed Web of Science ®Google Scholar
• JoshiMJoshiABartterTSymptom burden in chronic obstructive pulmonary disease and cancerCurr Opin Pulm Med20121829710322262138
   PubMed Web of Science ®Google Scholar
• PartridgeMRKarlssonNSmallIRPatient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet surveyCurr Med Res Opin20092582043204819569976
   PubMed Web of Science ®Google Scholar
• KesslerRPartridgeMRMiravitllesMSymptom variability in patients with severe COPD: a pan-European cross-sectional studyEur Respir J201137226427221115606
   PubMed Web of Science ®Google Scholar
• JenkinsCRCelliBAndersonJASeasonality and determinants of moderate and severe COPD exacerbations in the TORCH studyEur Respir J2012391384521737561
   PubMed Web of Science ®Google Scholar
• JonesPWBrusselleGDal NegroRWPatient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in EuropePrim Care Respir J201221332933622885563
   PubMedGoogle Scholar
• Espinosa de los MonterosMJPenaCSoto HurtadoEJJarenoJMiravitllesMVariability of respiratory symptoms in severe COPDArch Bronconeumol201248137 English, Spanish21944843
   PubMed Web of Science ®Google Scholar
• KimYJLeeBKJungCYPatient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL studyKorean J Intern Med201227442643523269884
   PubMed Web of Science ®Google Scholar
• SchnellKWeissCOLeeTThe prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008BMC Pulm Med2012122622695054
   PubMed Web of Science ®Google Scholar
• DonaldsonGCGoldringJJWedzichaJAInfluence of season on exacerbation characteristics in patients with COPDChest201214119410021799024
   PubMed Web of Science ®Google Scholar
• BarbaRZapateroALosaJEThe impact of weekends on outcome for acute exacerbations of COPDEur Respir J2012391465021659418
   PubMed Web of Science ®Google Scholar
• PartridgeMRMiravitllesMStåhlEKarlssonNSvenssonKWelteTDevelopment and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPDEur Respir J20103619610419897551
   PubMed Web of Science ®Google Scholar
• AgustiAHednerJMarinJMBarbéFCazzolaMRennardSNight-time symptoms: a forgotten dimension of COPDEur Respir Rev20112012118319421881146
   PubMedGoogle Scholar
• WoutersEFPostmaDSFokkensBCOSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study GroupWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax200560648048715923248
   PubMed Web of Science ®Google Scholar
• van den BergeMHopWCvan der MolenTCOSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study GroupPrediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary diseaseRespir Res2012134422672621
   PubMed Web of Science ®Google Scholar
• PartridgeMRSchuermannWBeckmanOPerssonTPolanowskiTEffect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPDTher Adv Respir Dis20093411119734176
   PubMedGoogle Scholar
• van der MolenTWillemseBWSchokkerSten HackenNHPostmaDSJuniperEFDevelopment, validity and responsiveness of the Clinical COPD QuestionnaireHealth Qual Life Outcomes200311312773199
   PubMedGoogle Scholar
• BerkhofFFBoomLNten HertogNEUilSMKerstjensHAvan den BergJWThe validity and precision of the Leicester Cough Questionnaire in COPD patients with chronic coughHealth Qual Life Outcomes201210422230731
   PubMed Web of Science ®Google Scholar
• YohannesAMRoomiJWinnSConnollyMJThe Manchester Respiratory Activities of Daily Living questionnaire: development, reliability, validity, and responsiveness to pulmonary rehabilitationJ Am Geriatr Soc200048111496150011083331
   PubMed Web of Science ®Google Scholar
• MonzBUSachsPMcDonaldJCrawfordBNivensMCTetzlaffKResponsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitisRespir Med2010104453454119917525
   PubMed Web of Science ®Google Scholar
• PokrzywinskiRFMeadsDMMcKennaSPGlendenningGARevickiDADevelopment and psychometric assessment of the COPD and Asthma Sleep Impact Scale (CASIS)Health Qual Life Outcomes200979819968881
   PubMed Web of Science ®Google Scholar
• MiravitllesMIriberriMBarruecoMLleonartMVillarrubiaEGaleraJUsefulness of the LCOPD, CAFS and CASIS Scales in understanding the impact of COPD on patientsRespiration Epub October 2, 2012
   Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarcia GilECaractaCFACCORD I study investigatorsEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• SobradilloPPozoFAgustíAP4 medicine: the future around the cornerArch Bronconeumol2011471354021190770
   PubMed Web of Science ®Google Scholar
• Rodríguez-RoisinRAgustíAThe GOLD initiative 2011: a change of paradigm?Arch Bronconeumol2012488286289 English, Spanish22537593
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Cit Care Med20091808741750
   PubMed Web of Science ®Google Scholar
• KatoMMakitaHUemuraKBronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trialAllergol Int201059328529320567133
   PubMedGoogle Scholar
• DecramerMRossiALawrenceDMcBryanDIndacaterol therapy in patients with COPD not receiving other maintenance treatmentRespir Med2012106121706171423031496
   PubMed Web of Science ®Google Scholar
• MrozRMMinarowskiLChyczewskaEIndacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patientsAdv Exp Med Biol2013756232822836615
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• SykesDADowlingMRLeighton-DaviesJThe Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropiumJ Pharmacol Exp Ther2012343252052822854200
   PubMed Web of Science ®Google Scholar
• GavaldàAMiralpeixMRamosICharacterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profileJ Pharmacol Exp Ther2009331274075119710368
   PubMed Web of Science ®Google Scholar
• VestboJVogelmeierCCreemersJFalquesMRiberaAGilEGOnset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPDCOPD20107533133620854047
   PubMedGoogle Scholar